{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-089564","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.412230+00:00","generated_at":"2026-05-17T06:43:07.658107+00:00","sec_items":["1.01","2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Traws Pharma acquires antiviral compound assets from Viriom for $2.35M cash","bullets":["Acquired IP and assets for pyrrolidine antiviral compound from Viriom for $2,350,000 cash paid on September 9, 2025.","Nikolay Savchuk, Traws COO, is Executive Chairman of Viriom; Dr. Robert Redfield, Traws CMO, on Viriom board; related-party transaction approved by audit committee.","Assets include patents, license agreements, regulatory filings, and materials exclusively related to the compound and program."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-089564","json":"https://secwatch.observer/filing/0001104659-25-089564.json","markdown":"https://secwatch.observer/filing/0001104659-25-089564.md","text":"https://secwatch.observer/filing/0001104659-25-089564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/tm2526017d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:43:07.658107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41d7deb65950edc38cb04a85f641e442a72ee147","claim":"Traws Pharma, Inc. completed an acquisition involving Virom, Inc. for $2,350,000 in cash (closed 2025-09-09).","evidence_excerpt":"On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001493152-26-025709","ticker":"NNE","company_name":"Nano Nuclear Energy Inc.","filed_at":"2026-05-29T10:30:26+00:00","headline":"Nano Nuclear acquires STS for up to $13M, adds nuclear logistics and $7.1M revenue","event_type":"m_and_a","sec_items":["1.01","2.01","3.02","5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: ma_transaction","same SEC item: 1.01, 2.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025709","json":"https://secwatch.observer/filing/0001493152-26-025709.json","markdown":"https://secwatch.observer/filing/0001493152-26-025709.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1923891/000149315226025709/0001493152-26-025709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1923891/000149315226025709/form8-k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm","comparable_excerpt":"“STS Acquisition”). The closing of the STS Acquisition occurred on May 22, 2026 (the “Closing Date”). Pursuant\nto the Purchase Agreement, the Buyer Parties agreed to pay up to $13.0 million in total consideration for STS, consisting of (i) approximately\n$6.0 million in cash (the “Closing Cash Consideration”), subject to adjustment under certain conditions within 180","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1923891/000149315226025709/0001493152-26-025709-index.htm"}},{"accession":"0001493152-26-025562","ticker":"BESS","company_name":"Bimergen Energy Corp","filed_at":"2026-05-28T13:28:23+00:00","headline":"Bimergen contributes 3 BESS projects to Cerberus JV; receives 7.5% equity + $1.18M cash","event_type":"m_and_a","sec_items":["1.01","2.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: ma_transaction","same SEC item: 1.01, 2.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025562","json":"https://secwatch.observer/filing/0001493152-26-025562.json","markdown":"https://secwatch.observer/filing/0001493152-26-025562.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1066764/000149315226025562/0001493152-26-025562-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1066764/000149315226025562/form8-k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm","comparable_excerpt":"Pursuant to the Contribution Agreement, Emergen contributed 100% of its equity interests in three battery energy storage system (“BESS”) project companies (the “Project Companies”), to the JV Company.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1066764/000149315226025562/0001493152-26-025562-index.htm"}},{"accession":"0001683168-26-004327","ticker":"TMGI","company_name":"Transglobal Management Group, Inc.","filed_at":"2026-05-27T23:04:33+00:00","headline":"TMGI acquires CSTI in all-stock deal, 50.6M shares issued","event_type":"m_and_a","sec_items":["1.01","2.01","3.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: ma_transaction","same SEC item: 1.01, 2.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004327","json":"https://secwatch.observer/filing/0001683168-26-004327.json","markdown":"https://secwatch.observer/filing/0001683168-26-004327.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434601/000168316826004327/0001683168-26-004327-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434601/000168316826004327/tmgi_8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm","comparable_excerpt":"Exchange Agreement (the “Agreement”) to\nacquire all of the outstanding shares of Continuum Software Technologies, Inc., a Wyoming corporation (hereafter, “CSTI”),\nin exchange for 50,645,000 shares of common stock (the “TMGI Common Stock”) of the Company (such transaction is hereafter\nreferred to as the “Acquisition”). CSTI possesses a cloud-based, all-in-one golf","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1434601/000168316826004327/0001683168-26-004327-index.htm"}},{"accession":"0001914496-26-000076","ticker":null,"company_name":"Sculptor Diversified Real Estate Income Trust, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Sculptor Diversified Real Estate acquires JW Marriott Marco Island for $835M via $690M loan, $87M equity","event_type":"m_and_a","sec_items":["1.01","2.01","2.03","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: ma_transaction","same SEC item: 1.01, 2.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001914496-26-000076","json":"https://secwatch.observer/filing/0001914496-26-000076.json","markdown":"https://secwatch.observer/filing/0001914496-26-000076.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1914496/000191449626000076/0001914496-26-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1914496/000191449626000076/sreit-20260501.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm","comparable_excerpt":"in 1982 and renovated in 2016) and the Lanai Tower (built in 2019). The MIH JV acquired a fee simple interest in the Property. The aggregate purchase price for the Property was $835.0 million. The acquisition was funded with $690 million of proceeds from the Loan (defined below) and the remainder from equity contributions from the members of the MIH JV (approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1914496/000191449626000076/0001914496-26-000076-index.htm"}},{"accession":"0001493152-26-021306","ticker":"OTLC","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Oncotelic completes merger transferring patent portfolio to Lunai for $20M Series B Preferred stock","event_type":"m_and_a","sec_items":["1.01","2.01","3.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: ma_transaction","same SEC item: 1.01, 2.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-021306","json":"https://secwatch.observer/filing/0001493152-26-021306.json","markdown":"https://secwatch.observer/filing/0001493152-26-021306.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/0001493152-26-021306-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/form8-k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm","comparable_excerpt":"greement and Plan of Merger (the “Merger Agreement”) with Lunai Bioworks, Inc., a Delaware corporation (“Lunai”),\nLunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of Lunai (“Merger Sub”), Neurobridge IP Holdings","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/0001493152-26-021306-index.htm"}},{"accession":"0001683168-26-003159","ticker":"IVHI","company_name":"Invech Holdings, Inc.","filed_at":"2026-04-23T23:59:59+00:00","headline":"Invech buys sportypick.com sports betting platform for 5M restricted shares of IVHI stock","event_type":"m_and_a","sec_items":["1.01","2.01","3.02","8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: ma_transaction","same SEC item: 1.01, 2.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-003159","json":"https://secwatch.observer/filing/0001683168-26-003159.json","markdown":"https://secwatch.observer/filing/0001683168-26-003159.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1009919/000168316826003159/0001683168-26-003159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1009919/000168316826003159/invech_8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm","comparable_excerpt":"has agreed to sell and the Company has agreed to purchase the website and total code of the sports betting platform\nwww.sportypick.com owned by Day (the “Assets”) in exchange for 5,000,000 restricted shares of common stock of the Company\n(the “Shares”). The foregoing information is a summary of the\nAPA involved in the transaction described above, is not complete,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1009919/000168316826003159/0001683168-26-003159-index.htm"}},{"accession":"0001731122-26-000555","ticker":"VWAV","company_name":"VisionWave Holdings, Inc.","filed_at":"2026-04-13T23:59:59+00:00","headline":"VisionWave acquires xClibre AI video IP for 7M shares + $6M note; $60M valuation","event_type":"m_and_a","sec_items":["1.01","2.01","3.02","9.01","8.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: ma_transaction","same SEC item: 1.01, 2.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000555","json":"https://secwatch.observer/filing/0001731122-26-000555.json","markdown":"https://secwatch.observer/filing/0001731122-26-000555.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2038439/000173112226000555/0001731122-26-000555-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2038439/000173112226000555/e7553_8-k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm","comparable_excerpt":"Company”) entered into an Asset Purchase Agreement (the “Agreement”) with Dream America Marketing Services, Ltda.,\na Costa Rican company (the “Seller”). Pursuant to the Agreement, the Company agreed to acquire","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2038439/000173112226000555/0001731122-26-000555-index.htm"}},{"accession":"0001193125-26-251540","ticker":"CYH","company_name":"COMMUNITY HEALTH SYSTEMS INC","filed_at":"2026-06-01T20:30:16+00:00","headline":"Community Health Systems closes sale of four Arkansas hospitals for $110M cash to Freeman Health System","event_type":"m_and_a","sec_items":["2.01","9.01","8.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: ma_transaction","same SEC item: 2.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251540","json":"https://secwatch.observer/filing/0001193125-26-251540.json","markdown":"https://secwatch.observer/filing/0001193125-26-251540.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108109/000119312526251540/0001193125-26-251540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108109/000119312526251540/cyh-20260601.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm","comparable_excerpt":"the closing of the Transaction, after giving effect to estimated working capital, the assumption of finance leases by the Purchaser and before certain transaction expenses, was $110 million in cash (subject to a post-closing working capital adjustment). The foregoing summary of the Transaction and the terms and conditions of the Purchase Agreement is subject to, and","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1108109/000119312526251540/0001193125-26-251540-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}